[Ip-health] AP: Health experts slam US deal for large supply of virus drug

Aidan Hollis ahollis at ucalgary.ca
Thu Jul 2 10:35:34 PDT 2020

Of course, it appears that some or all of Gilead's remdesivir is actually manufactured in Canada, in any case:

If Canada were to block exportation of this drug, no manufacturer would ever locate here again. Ward’s claim, in other words, can only ever work for big, rich countries. You can’t be a bully without the muscle to go with it and a poorly developed ethical compass.

(FWIW, remdesivir has not yet been approved for use by Health Canada. It is apparently being reviewed on an expedited basis.

Aidan Hollis
Professor of Economics
University of Calgary
ahollis at ucalgary.ca<mailto:ahollis at ucalgary.ca>
+1 403 220 5861

twitter: @aidanhollis

Incentives for Global Health

The University of Calgary is located on the traditional territories of the people of the Treaty 7 region in Southern Alberta, which includes the Siksika, Piikani, Kainai, Tsuut’ina, Chiniki, Bearspaw, and Wesley First Nations.

On Jul 2, 2020, at 9:20 AM, Baker, Brook <b.baker at northeastern.edu<mailto:b.baker at northeastern.edu>> wrote:


It's really pretty stunning that academics like Dr. Penny Ward can not only defend high prices but also nationalistic stockpiling of medicines that leaves 95+% of the global population waiting in line for months for one of the first medicines that can treat severe COVID-19 illness.  The US gobbled up 60% of Gilead's initial donations of remdesivir (900,000 of 1,500,000 doses) and now it is gobbling up 93% of the next three months' supply.  Just because countries can and have done things doesn't make it morally or ethically "reasonable."

   Dr. Penny Ward of King’s College London, noted that many countries have
   legal provisions that allow them to prohibit the exportation of drugs to
   other countries during an emergency.

   “It is unreasonable to expect that the U.S. government should deny their
   population access to drugs manufactured in the USA,” she said.

   Ward pointed out that another drug that may help people with severe
   COVID-19, the cheap steroid dexamathasone, is long off-patent and available


Professor Brook K. Baker
Northeastern U. School of Law
416 Huntington Ave.
Boston, MA 02115
Honorary Research Fellow, University of KwaZulu Natal
Health GAP (Global Access Project) Senior Policy Analyst
(w) 617-373-3217
(c) 617-259-0760
b.baker at northeastern.edu<mailto:b.baker at northeastern.edu>
Skype:  brook_baker

Ip-health mailing list
Ip-health at lists.keionline.org

More information about the Ip-health mailing list